Sams, L.
Kruger, S.
Heinemann, V.
Bararia, D.
Haebe, S.
Alig, S.
Haas, M.
Zhang, D.
Westphalen, C. B.
Ormanns, S.
Metzger, P.
Werner, J.
Weigert, O.
von Bergwelt-Baildon, M.
Rataj, F.
Kobold, S.
Boeck, S. http://orcid.org/0000-0002-1922-2127
Funding for this research was provided by:
Friedrich-Baur-Stiftung (43/16)
Ludwig-Maximilians-Universität München
Article History
Received: 13 February 2021
Accepted: 2 April 2021
First Online: 19 April 2021
Declarations
:
: S. Kobold received research support from TCR2 Inc. and Arcus Biosciences outside the submitted work. S. Boeck reports personal fees from Celgene, AstraZeneca and Servier (honoraria for scientific presentations and paid consultant), as well as research support from Celgene outside the submitted work. All other authors declare no conflict of interest.
: The study was conducted in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines, and local regulatory requirements. The study protocol was reviewed and approved by the Ethics Committees of Ludwig-Maximilians-University, Munich, Germany (approval number 284-10), and written informed consent was obtained from each patient before any study specific procedure.